Regulatory agencies, such as the FDA, are closely monitoring these findings and have recently advised caution regarding the use of GLP-1 drugs for people who may already be at higher risk of DVT
Clinical safety guidance suggests that semaglutide may still be safe if: Exposure was brief Temperature limits were not exceeded The medication shows no visible changes However, pharmaceutical safety standards recommend discarding biologic medications if storage conditions are uncertain, as visual inspection alone cannot confirm potency
Recommendations for Healthcare Providers Doctors are advised to carefully review a patients full medical history before starting semaglutide, especially in women who have had hormonal imbalances, irregular periods, uterine fibroids, or endometriosis
The other trial tested orforglipron, a different oral GLP-1 made by the pharmaceutical company Eli Lilly
Using a tirzepatide dosage calculator and the tirzepatide compound dosage chart helps ensure accuracy